ApoB, LDL and Cardiovascular Risk — Looking Beyond the Standard Cholesterol Test

I often come across voices on social media that push the view that cholesterol — and in particular LDL cholesterol, a measure I frequently use in my medical practice — is not a real cause of heart attacks and strokes. These voices often cite trials in which people with normal LDL still had cardiovascular events, and conclude that LDL cannot be the driver. The mainstream scientific and medical consensus, by contrast, is that elevated atherogenic lipoproteins are one of the central causes of heart disease, stroke, kidney failure and contribute to dementia.

Both views can’t be right — so why is there such a diversity of opinion, and what does the evidence actually show?

The science is clear: atherogenic lipoproteins are causal in atherosclerosis. The question for prevention is not whether to take them seriously — it is how to measure them well, and that is where ApoB enters the picture.

The standard cholesterol test

A standard lipid profile usually reports total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides. LDL cholesterol is often described as “bad cholesterol” — a phrase that oversimplifies. LDL particles have normal biological roles, but when atherogenic lipoproteins are present in excess over time, they drive plaque formation in the artery wall.

LDL cholesterol measures the mass of cholesterol carried within LDL particles. For many people, this is a reasonable estimate of cardiovascular risk. Higher LDL cholesterol generally means higher risk, especially over a lifetime.

LDL cholesterol is not a direct count of particles. Two people can have the same LDL cholesterol but different numbers of LDL particles. One may have fewer cholesterol-rich particles. Another may have many smaller cholesterol-depleted particles — and in the second person, more atherogenic particles are entering the artery wall, even though the number on the report looks similar.

This is where ApoB becomes useful.

What ApoB is

ApoB is a structural protein found on the surface of all the main atherogenic lipoprotein particles — LDL, VLDL remnants, IDL and lipoprotein(a). Each of these particles carries one ApoB molecule. ApoB is therefore a practical proxy for the number of atherogenic particles in circulation.

This matters because atherosclerosis is driven by particles entering and being retained in the arterial wall. The more atherogenic particles circulating over time, the greater the opportunity for plaque to form. Cholesterol content matters, but particle number is closer to the actual mechanism of disease.

A simple analogy: LDL cholesterol tells us how much cargo is on the road. ApoB tells us how many vehicles. For artery wall exposure, the number of vehicles matters most.

When LDL and ApoB disagree

In many people, LDL cholesterol and ApoB move together. If LDL cholesterol is high, ApoB is usually high. There are common situations where they diverge.

Discordance is more likely in people with insulin resistance, type 2 diabetes, abdominal adiposity, high triglycerides, metabolic syndrome or fatty liver. In these settings, the number of atherogenic particles is often higher than the LDL cholesterol level suggests.

This creates false reassurance. A person may be told their LDL cholesterol is only mildly elevated, while their ApoB reveals a much higher burden of atherogenic particles. The reverse can also happen — LDL cholesterol that looks elevated, with an ApoB that is less concerning. This does not mean LDL can be ignored, but it does mean the risk picture is not always what a single number implies.

Why this matters for prevention

The purpose of risk detection is not to generate more numbers. It is to identify preventable risk early enough to act.

Cardiovascular prevention works best before symptoms appear. Once a person has angina, a myocardial infarction or a stroke, the disease process is already established. Earlier detection allows earlier decisions about lifestyle, blood pressure, glucose, smoking, weight, sleep apnoea, medications and more intensive lipid lowering when appropriate.

ApoB is particularly useful when I want to know whether someone’s lipid-related risk is greater than the standard panel suggests. It is also useful for monitoring response to therapy, because lowering ApoB means reducing the number of atherogenic particles.

In longevity medicine, the question is rarely “is this result inside the laboratory reference range?” It is “is this level appropriate for this person’s long-term risk?” Those are different questions, and they often have different answers.

Lifetime exposure matters

Atherosclerosis is strongly influenced by cumulative exposure. A moderately elevated ApoB or LDL over 30 years can be more important than a very high level discovered late.

This is one reason midlife risk assessment matters so much. A person in their 40s or 50s may have a low short-term risk of a cardiovascular event, but a high lifetime risk if their lipid profile, blood pressure, glucose or other risk factors remain elevated.

Traditional risk calculators have a real limitation here — they tend to understate risk in younger adults because age is such a dominant variable. A 45-year-old with significant lipid abnormalities may still appear “low risk” over five years, while accumulating arterial injury that becomes clinically important later.

Prevention requires thinking in decades, not in five-year intervals.

ApoB is not the whole story

ApoB is useful, but it is not a complete cardiovascular assessment. Risk is multifactorial — blood pressure, smoking, diabetes, kidney disease, family history, inflammatory disease, sleep apnoea, physical inactivity, diet quality and socioeconomic factors all matter.

Lipoprotein(a), or Lp(a), is another important inherited risk factor that is not captured by a standard lipid panel and should be measured at least once in adult life. Coronary artery calcium scoring is also useful in selected patients when risk remains uncertain.

The best approach is integrated. ApoB should be interpreted in the context of the person, not in isolation.

What patients should ask

A useful conversation with a doctor might include:

• What is my overall cardiovascular risk?
• Is my LDL cholesterol appropriate for my risk level?
• Would ApoB help clarify my risk?
• Should I have Lp(a) measured at least once?
• Are my blood pressure, glucose and waist circumference contributing to risk?
• Would coronary calcium scoring be useful in my case?
• What level of lipid lowering is appropriate for prevention?

The answer will differ depending on age, history and existing disease. But these are the right questions.

The bottom line

Based on the arguments I’ve laid out, the conclusion is clear to me. Atherogenic lipoproteins are causal in cardiovascular disease, and how we measure them matters. Standard cholesterol testing remains useful, but it does not always show the full picture. ApoB provides a clearer estimate of the number of atherogenic particles that contribute to plaque formation.

The good news is that this is a risk factor we can mitigate. For prevention-focused care, earlier and more precise risk detection means better decisions before disease becomes clinically obvious. The aim is not to medicalise everyone — it is to identify modifiable risk early enough to prevent events that may appear sudden, but were developing for decades.